Skip to main content

David Yeazel, MS, MPH

David Yeazel brings a unique perspective to LDN, combining expertise in basic and clinical biomedical research with their clinical applications to patient populations.  After pursuing undergraduate studies in Psychobiology at Oberlin College, his initial research interests were within primatology, being awarded a Watson Fellowship for studies within comparative primatology in Africa and Asia.

At Yale Medical School he pursued graduate studies in neuropharmacology and psychoneuroimmunology, working towards improved treatment protocols for patients suffering from Parkinson’s disease and schizophrenia.  He worked as part of the research team headed by Dr. Patricia Goldman-Rakic which helped to refine the basic understanding of the neuroanatomical and neurophysiological dysfunctions present in schizophrenia, translating those discoveries into clinically useful pharmacological and behavioral treatment protocols.

His research interests broadened into functional medicine as a means to help patients across a wider spectrum of both disease states and health promotion.  This involved additional graduate studies in the form of a Master’s degree in Public Health from Yale Medical School, with concentrations in Health Services Administration/Public Policy, and disaster management.   David spent a year in Zimbabwe as part of a joint medical relief project with Yale and the World Health Organization working on a medical relief mission in Zimbabwe, bringing mobile aids clinics to remote regions of the country inaccessible to traditional medical care.

At Mayo Clinic David helped to conduct research into the effectiveness of mindfulness as a treatment protocol to combat chronic pain.

At Hoey Apothecary, David has sought to combine clinical and basic pharmacology research to help educate clinical providers as to the unique nature of what LDN is, and can accomplish—both in terms of its clinical applications, and the acute need for an understanding of dosing protocols to help them achieve therapeutic success for their patients.